Management of the incidents of VTE in cancer patients
During the ICTHIC webinar, “Updates in cancer-associated thrombosis,” Dr. Luis Jara-Palomares gave a lecture on the...
Thrombosis and cancer
Management of VTE beyond 12 months in patients with cancer-associated thrombosis
During the ICTHIC webinar, “Long-term treatment & DDI implications in the management of CAT,” Dr. Luis...
Real-world CAT patient profile from the RIETE registry
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?”, Dr. Laurent Bertoletti gave a...
A novel biomarker for chemotherapy-associated venous thromboembolism
Ovarian cancer patients are at high risk of venous thromboembolism (VTE). More than 80% of women present with a...
Chronic Kidney disease in CAT patients
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?” Dr. Corinne Isnard Bagnis gave a...
Cancer genetic alterations and risk of venous thromboembolism
During the 11th ICTHIC, Simon Mantha talked about the relationship between genetic cancer alteration and the risk of...
PODCAST. Drug-drug interactions: Implications for anticoagulation use in patients with cancer
Cancer patients have an increased risk of VTE by at least 12-fold, and cancer therapies increase the risk of VTE by a...
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
Evolving data on cardiovascular complications in cancer
During the 11th ICTHIC, Hugo Ten Cate talked about the evolving data on cardiovascular complications in cancer. Here,...